Denali Therapeutics Inc.

03/09/2022 | Press release | Distributed by Public on 03/09/2022 07:10

Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)